Meloxicam and Filgrastim in Collecting Peripheral Blood Stem Cells for Transplant in Patients with Multiple Myeloma, Hodgkin Lymphoma, or Non-Hodgkin Lymphoma

Inclusion Criteria

• Has provided written informed consent prior to completing any study procedures
• Patients must have a previously documented histologic diagnosis of multiple myeloma (MM) Hodgkin’s Disease (HD) or non-Hodgkin’s lymphoma (NHL), and be eligible to undergo autologous PBSC transplantation on institutional protocols * Multiple myeloma should be in first or second partial response or better, as defined by International Myeloma Working Group criteria * Hodgkin’s Disease should be primary refractory or relapsed (either chemosensitive or refractory) * Non-Hodgkin’s lymphoma must be in either first or second partial response or better and have any one of the following histologies: ** Diffuse large B cell lymphoma ** Transformed lymphoma ** Mantle cell lymphoma ** Follicular lymphoma (any grade) ** Peripheral T cell lymphoma
• Karnofsky performance status of at least 70%
• Serum bilirubin =< twice the upper limit of normal
• Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< twice the upper limit of normal
• Serum creatinine =< 2.0 mg/dl
• Urine M-protein =< 1 g/24 hours (MM patients only)
• One of the following must be satisfied: * The patient is undergoing mobilization to collect and store for an autologous PBSC transplant in the future * The patient is eligible to undergo autologous PBSC transplantation on institutional protocols in the future
• Left ventricular ejection fraction >= 45%
• Corrected diffusing capacity of the lung for carbon monoxide (DLCO) >= 50%
• No prior attempt at mobilizing PBSC
• Patients must be at least 4 weeks from last cytotoxic chemotherapy (including alkylating, anthracyclines, epipodophyllotoxins, and platinum drugs), or immunomodulatory drugs (including lenalidomide or pomalidomide, or related derivatives) at time of treatment on this protocol
• Patients must be at least 2 weeks from last treatment with a proteasome inhibitor (e.g., bortezomib, carfilzomib) at time of treatment on this protocol
• Patients must be negative for human immunodeficiency virus (HIV)
• Women of childbearing potential must have a negative pregnancy test (urine or serum) and must not be lactating at the time of informed consent * Women and men must use adequate birth control while taking part in this study (such as a condom or diaphragm with contraceptive cream/jelly, birth control pills, Norplant, abstinence [no sexual intercourse] or surgical sterilization)

Exclusion Criteria

• Patients must not have received radiation therapy within the past 4 weeks
• Patients must not have received radiation therapy to more than 20% of hematopoiesis forming bones (spine, pelvis and proximal long bones) during lifetime
• Patients must not have active central nervous system involvement
• Patients must not have a prior autologous, syngeneic or allogeneic hematopoietic stem cell transplant
• Patients must not have received prior bone seeking radionuclides
• Patients must not have received myeloid growth factors within 2 weeks before mobilization attempt on this study
• Patients must not have taken nonsteroidal anti-inflammatory drugs (NSAID) in the past 14 days before treatment on this protocol
• Patients must not have nor had active or recent peptic ulcer disease within the past 6 months * Patients with active significant symptoms of dyspepsia will be excluded
• Patients with a history of asthma will be excluded